Home / Pharmaceutical company intelligence
TABROS PHARMA (PVT). LTD. site mark
Pharmaceutical company intelligence

TABROS PHARMA (PVT). LTD.

Private pharmaceutical manufacturer · Karachi · Pakistan

Pakistan pharmaceutical manufacturer and marketer with a broad branded portfolio and dedicated pharmacovigilance and product-safety functions.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date29 Jul 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Tabros Pharma (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
Essa House, 32-1-C, Block-6, P.E.C.H.S., Karachi, Pakistan
Phone
+92 21 34533416-8
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000106 Tabros Pharma (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000106 182 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx188public portfolio records represented
REG139unique registrations represented
IDX96indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR179current validated price records
G65generic molecules in indexed catalogue
DF13dosage-form groups
TA12therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage95%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixTABROS PHARMA (PVT). LTD.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/tabros-pharma-pvt-ltdGenerated 25 Sep 2026Anti-infectives98 · 55%Cardiovascular17 · 9%Vitamins, minerals & nutrition16 · 9%Gastrointestinal & hepatology12 · 7%Hematology & thrombosis9 · 5%Pain & musculoskeletal8 · 4%Cross-therapeutic & anti-inflamma…7 · 4%Other therapeutic areas12 · 7%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioTABROS PHARMA (PVT). LTD.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/tabros-pharma-pvt-ltdGenerated 25 Sep 2026179presentationsTablet84 · 47%Injection40 · 22%Capsule12 · 7%Suspension12 · 7%Solution7 · 4%Infusion6 · 3%Other forms18 · 10%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionTABROS PHARMA (PVT). LTD.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/tabros-pharma-pvt-ltdGenerated 25 Sep 2026165comparable productsBelow peer median45 · 27%Near peer median61 · 37%Above peer median59 · 36%Company median price position+0.8%Lowest-price equivalents11Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsTABROS PHARMA (PVT). LTD.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/tabros-pharma-pvt-ltdGenerated 25 Sep 2026Nabiqasim Industries (Pvt) Ltd.,41 shared63% overlapAtco Laboratories Limited39 shared60% overlapMacter International Limited39 shared60% overlapSAMI Pharmaceuticals Pvt. Ltd.39 shared60% overlapNovaMed Pharmaceuticals(Pvt.)Ltd39 shared60% overlapM/s. Genix Pharma (Pvt) Ltd.38 shared58% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives98 products · 55%
Cardiovascular17 products · 9%
Vitamins, minerals & nutrition16 products · 9%
Gastrointestinal & hepatology12 products · 7%
Hematology & thrombosis9 products · 5%
Pain & musculoskeletal8 products · 4%
Cross-therapeutic & anti-inflammatory7 products · 4%
Endocrine & metabolic6 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins21 products · 12%
Vitamins / minerals / hematinics16 products · 9%
Antimalarials15 products · 8%
Antivirals11 products · 6%
Antiemetics9 products · 5%
Macrolide antibacterials9 products · 5%
Analgesics / NSAIDs8 products · 4%
Antifungals7 products · 4%
Formulation footprint

Dosage forms

Tablet84 products
Injection40 products
Capsule12 products
Suspension12 products
Solution7 products
Infusion6 products
Lotion4 products
Syrup4 products
Cream3 products
Gel3 products
Sachet2 products
Ointment1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 DENCITYOndansetron 9presentations 4 mg, 4 MG/2 mL, 4 mg/5 mL, 8 mg · Tablet, Injection, Solution #2 LIZOTEKLinezolid 6presentations 100 mg/5 mL, 2 mg, 600 mg · Suspension, Infusion, Tablet #3 ColimethateColistimethate sodium 5presentations 1 MIU, 2 MIU, 3 MIU (≈100 mg colistin base activity), 4.5 MIU · Injection, Infusion #4 CUTISTerbinafine 5presentations 1%, 1% w/v, 1% w/w (10 mg/g), 10 mg · Gel, Lotion, Cream #5 FERRYIron polymaltose complex 5presentations 100 mg, 50 mg elemental iron/5 mL, 50 mg/5 mL · Capsule, Syrup #6 KINRAAzithromycin 5presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4527% of comparable products
Near market median61within ±5% of median
Above market median5936% of comparable products
Lowest-price equivalents11ties included
Company median price position +0.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
LOMIS 75 mgAcetylsalicylic acid (Aspirin) · Tablet · 50's PKR 0.08/tablet-95.9% vs market median Water for Injection 5 mLWater for Injection · Injection · 5ml x 100's PKR 0.11/mL-94.7% vs market median LOMIS 75 mgAcetylsalicylic acid (Aspirin) · Tablet · 100's PKR 0.22/tablet-89.2% vs market median PARTAM 120 mg/5 mLParacetamol · Oral solution · 450ml PKR 0.17/mL-82.9% vs market median ASCORBIC ACID Ascorbic Acid 100 mgAscorbic acid · Tablet · 1000's PKR 0.11/tablet-76.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 41shared generics Atco Laboratories Limited278 products · 94 generics 39shared generics Macter International Limited256 products · 93 generics 39shared generics SAMI Pharmaceuticals Pvt. Ltd.194 products · 63 generics 39shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 39shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 38shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers133Distinct registrations among indexed, published, presentation-validated products only
Verified price observations179
Products with a verified price179
Products with multiple price observations0
Source records with multiple versions176
Latest portfolio source check22 Sep 2026
Latest effective price date29 Jul 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

139 unique registration(s) · 96 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
LIZOTEK Linezolid 600 mg Tablet 12's 053202 PKR 4,719.87 PKR 393.32/tablet Near median
LIZOTEK Linezolid 2 mg IV infusion 100ml 057938 PKR 638.91 PKR 6.39/mL 44% above median
LIZOTEK Linezolid 2 mg IV infusion 200ml 057939 PKR 738.62 PKR 3.69/mL 36% below median
LIZOTEK Linezolid 2 mg IV infusion 300ml 057940 PKR 1,107.96 PKR 3.69/mL 36% below median
LIZOTEK Linezolid 100 mg/5 mL Oral suspension 60ml 057941 PKR 646.31 PKR 10.77/mL 59% above median
LIZOTEK Linezolid 100 mg/5 mL Oral suspension 120ml 057941 PKR 1,228.07 PKR 10.23/mL 51% above median
MECROZ 2% ORAL Miconazole 2 % Gel 20gm 086115 PKR 177.12 PKR 8.86/g Near median
MISOMAL Artemether 20 mg/mL Injection 6X1ML 039217 PKR 619.55 PKR 103.26/mL 9% above median
MISOMAL Artemether 80 mg/mL Injection 6X1ML 042500 PKR 1,239.07 PKR 206.51/mL 11% above median
MISOMAL Artesunate 500 mg Tablet 3+6 047120 PKR 193.89 — No comparator
MISOMAL Artemether 40 mg/mL Injection 10X1ML 066759 PKR 1,239.07 PKR 123.91/mL 6% above median
MISONATE Artesunate 60 mg Injection VIAL 057719 PKR 247.81 PKR 247.81/vial/unit Near median
MISONATE Artesunate 120 MG Injection VIAL 083299 PKR 407.17 PKR 407.17/vial/unit Near median
MISONATE Artesunate 30 MG IV/IM injection 1's 092645 PKR 139.77 PKR 139.77/vial/unit No comparator
MIXTE Hydroxychloroquine 200 mg Tablet 5x10's 101298 PKR 680.21 PKR 13.60/tablet 6% below median
MIXTE Hydroxychloroquine 200 mg Tablet 3x10's 101298 PKR 408.12 PKR 13.60/tablet 6% below median
MOXIFO Moxifloxacin 400 MG Tablet 5'S 048764 PKR 922.11 PKR 184.42/tablet Near median
NISITA Daclatasvir 60 mg Tablet 28's 089082 PKR 9,078.99 PKR 324.25/tablet Near median
REVERTA Lopinavir + Ritonavir 200 mg + 50 mg Tablet 120's 101299 PKR 11,608.76 PKR 96.74/tablet Near median
RONIL Ceftriaxone 250 mg Injection VIAL 021805 PKR 291.97 PKR 291.97/vial/unit 52% above median
RONIL Ceftriaxone 500 mg Injection VIAL 021806 PKR 501.27 PKR 501.27/vial/unit 54% above median
RONIL Ceftriaxone 250 mg Injection VIAL 021808 PKR 291.97 PKR 291.97/vial/unit 52% above median
RONIL Ceftriaxone 500 mg Injection VIAL 021809 PKR 501.27 PKR 501.27/vial/unit 54% above median
RONIL RA Ceftriaxone 1 G Injection VIAL 021807 PKR 985.26 PKR 985.26/vial/unit 64% above median
RONIL RA Ceftriaxone 1 G Injection VIAL 021810 PKR 880.84 PKR 880.84/vial/unit 47% above median
SCABRID Permethrin 5% Cream 30gm 055452 PKR 122.76 PKR 4.09/g Near median
SCABRID Permethrin 5% Lotion 120ML 055453 PKR 330.06 PKR 2.75/mL Near median
SCABRID Permethrin 5 % Lotion 60ML 055453 PKR 165.22 PKR 2.75/mL 5% above median
SCABRID Permethrin 5 % Lotion 240ML 055453 PKR 542.90 PKR 2.26/mL 14% below median
SUINT Ivermectin 6 mg Tablet 10's 073720 PKR 489.34 PKR 48.93/tablet 10% below median
TABROGYL Metronidazole 200 mg Tablet 1000's 005203 PKR 1,061.52 PKR 1.06/tablet 51% below median
TABROGYL Metronidazole 200 mg Tablet 100's 005203 PKR 199.35 PKR 1.99/tablet 7% below median
TABROGYL Metronidazole 400 mg Tablet 100's 011435 PKR 352.21 PKR 3.52/tablet 19% above median
TABROGYL Metronidazole 200 mg/5 mL Suspension 60ml 019257 PKR 51.34 PKR 0.86/mL 7% below median
VIBRENTA Sofosbuvir 400 mg Tablet 28'S 080177 PKR 12,118.01 PKR 432.79/tablet Near median
VIBRENTA-VPT 400mg Sofosbuvir + Velpatasvir 400 mg + 100 mg Tablet 28'S 089071 PKR 19,945.06 PKR 712.32/tablet Near median
VIRENTA Entecavir 0.5 mg Tablet 3X10'S 086874 PKR 12,964.31 PKR 432.14/tablet 21% above median
VIZOR Levofloxacin 250 mg Tablet 10's 032147 PKR 480.11 PKR 48.01/tablet Near median
VIZOR Levofloxacin 500 MG Tablet 10's 032148 PKR 775.57 PKR 77.56/tablet Near median
Zatron Ceftazidime 250 mg Injection 1 vial 021811 PKR 159.65 PKR 159.65/vial/unit Near median
Zatron Ceftazidime 500 mg Injection 1 vial 021812 PKR 242.83 PKR 242.83/vial/unit Near median
Zatron Ceftazidime 1 g Injection 1 vial 021813 PKR 456.12 PKR 456.12/vial/unit Near median
ZINGER Ribavirin 400 mg Capsule 1x10's 023820 PKR 572.45 PKR 57.25/capsule Near median
ZINGER Ribavirin 100 mg Capsule 1x10's 026887 PKR 267.76 PKR 26.78/capsule Near median
ZINGER Ribavirin 200 mg Capsule 1x10's 026888 PKR 406.26 PKR 40.63/capsule 15% below median
ZINGER Ribavirin 600 mg Tablet 1x10's 027151 PKR 914.07 PKR 91.41/tablet 274% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). TABROS PHARMA (PVT). LTD — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/tabros-pharma-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.